CNS Pharmaceuticals (CNSP) Research & Development (2018 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Research & Development came in at $3.2 million in Q4 2025, up 111.27% YoY from $1.5 million in Q4 2024, and up 44.08% on a QoQ basis from $2.2 million in Q3 2025.
CNS Pharmaceuticals (CNSP) Research & Development (2018 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 8 years of Research & Development data on file, last reported at $3.2 million in Q4 2025.
- Quarterly Research & Development rose 111.27% year-over-year to $3.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.8 million (up 5.19% YoY) and the FY2025 annual result came in at $9.8 million, up 5.19% from the prior year.
- Research & Development grew to $3.2 million in Q4 2025, from $2.2 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $4.3 million in Q4 2023 to a low of $1.1 million in Q2 2024.
- A 5-year average of $2.6 million and a median of $2.5 million in 2021 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2021 — Research & Development surged 259.97% — and 2024, when it tumbled 64.93%.
- Tracing CNSP's Research & Development over 5 years: stood at $2.4 million in 2021, then gained by 26.61% to $3.0 million in 2022, then surged by 43.25% to $4.3 million in 2023, then plunged by 64.93% to $1.5 million in 2024, then soared by 111.27% to $3.2 million in 2025.
- The last three Research & Development figures came in at $3.2 million (Q4 2025), $2.2 million (Q3 2025), and $1.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | CNS Pharmaceuticals | 2.64 Mn | -4.56 Mn | - | 3.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.17 Mn |
| Sep 30, 2025 | 2.20 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | 3.24 Mn |
| Dec 31, 2024 | 1.50 Mn |
| Sep 30, 2024 | 4.24 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Mar 31, 2024 | 2.43 Mn |
| Dec 31, 2023 | 4.27 Mn |
| Sep 30, 2023 | 3.41 Mn |
| Jun 30, 2023 | 2.85 Mn |
| Mar 31, 2023 | 3.57 Mn |
| Dec 31, 2022 | 2.98 Mn |
| Sep 30, 2022 | 2.21 Mn |
| Jun 30, 2022 | 2.22 Mn |
| Mar 31, 2022 | 1.89 Mn |
| Dec 31, 2021 | 2.36 Mn |
| Sep 30, 2021 | 2.58 Mn |
| Jun 30, 2021 | 2.66 Mn |
| Mar 31, 2021 | 2.21 Mn |